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Iron depletion-induced down-regulation of N-cadherin expression inhibits invasive 
malignant phenotypes in human esophageal cancer. 
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Abstract 
 Esophageal carcinomas often have a poor prognosis due to early lymph node metastasis. 
Epithelial-mesenchymal transition (EMT) is strongly associated with the acquisition of cancer 
metastasis and invasion. However, there is no established treatment to eliminate the EMT of cancer 
cells. Iron is an essential element for both normal and cancer cells in humans. Recently, iron depletion 
has been discovered to suppress tumor growth. Therefore, we hypothesized that decreased iron 
conditions would regulate EMT phenotypes, as well as suppressing tumor growth. The human 
esophageal cancer cell lines TEs and OE19 were used in our study. Decreased iron conditions were 
made using an iron-depletion diet in mice and the iron chelator deferasirox for cell studies. Migration 
and invasion abilities of cells were measured using migration, invasion, and sphere-formation assays. 
Esophageal subcutaneous tumor growth was suppressed in decreased iron conditions. In vitro study 
showed that decreased iron conditions inhibited esophageal cancer cell proliferation as well as 
migration and invasion abilities, with down-regulation of N-cadherin expression. Also, migration and 
invasion abilities were suppressed by inhibiting expression of N-cadherin. In conclusion, decreased iron 
conditions revealed a profound anti-cancer effect by the suppression of tumor growth and the inhibition 
of migration and invasion abilities via N-cadherin. 
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Introduction 
 Esophageal carcinoma, with a 5-year survival rate of 15–20% (1, 2), is one of the most 
common causes of cancer death worldwide and is rapidly increasing in incidence (3). It has recently 
been reported that the best outcomes are associated with early stage diagnosis (4). The prognosis is 
often poor for esophageal carcinomas due to early lymph node metastasis even in the superficial stage 
and its invasiveness to neighboring organs such as the aorta, trachea, and lung. Therefore, regulation of 
the aggressive metastatic features of esophageal cancer can be essential for improving patient survival. 
Various experimental approaches have been implemented to identify the molecules involved in 
metastasis processes including migration and invasion (5, 6). However, the underlying mechanisms 
remain unclear. 
 There is widespread belief that the phenomenon of epithelial-mesenchymal transition (EMT) is 
strongly associated with the acquisition of cancer metastasis and invasion. Epithelial cells have 
sheet-like morphology and have close contact with neighboring cells at cell junctions (7). Once EMT 
occurs, cancer cells lose their tight contacts and become isolated and motile, and modulate the 
organization of their cytoskeletal systems (8, 9). Afterwards, the cancer cells acquire the ability to 
invade the basement membrane around the cells into the blood vessels, when invasion and metastasis 
become possible (10). However, invasion and metastasis are exceedingly complex processes, and their 
mechanisms remain incompletely understood. One of our focuses has been the role of cadherins in 
cancer progression. Cadherin function is critical in normal development, and its alteration has been 
implicated in tumorigenesis (11). It is well established that E-cadherin functions as a tumor suppressor, 
while studies have shown that expression of an inappropriate cadherin in epithelial cells is another way 
that tumor cells can alter their adhesive function (12, 13). EMT is often accompanied by loss of 
E-cadherin function and increased expression of other cadherins such as N-cadherin, which is thought to 
play a fundamental role in the early steps of invasion and metastasis of pancreatic cancer (14-16). These 
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data led us to ask whether blocking the function of N-cadherin would prevent the malignant behavior of 
N-cadherin-expressing esophageal cancer cells. 
 While iron is an essential trace element, its overload induces some types of cancer, which 
suggests that its manipulation can be a therapeutic target in cancer (17, 18). Iron deficiency has also 
been reported to suppress tumor growth in vivo (19). However, its efficacy as a single agent is not 
superior to standard chemotherapy, and it seems unsuitable as a single-agent standard therapeutic 
strategy. We previously reported that iron depletion strongly suppressed tumor growth via cell-cycle 
arrest when combined with an ordinary molecular targeting drug (20). Recently, it has been reported 
that transforming growth factor (TGF)-induced EMT via up-regulation of NDRG1 can be controlled by 
iron chelation, suggesting that iron might be an essential element of EMT (21). However, the 
mechanisms have not been elucidated and further investigation is required. We hypothesize that iron 
depletion might prevent invasion and migration of cancer cells by regulation of EMT-related molecules, 
as well as inducing tumor regression by inhibiting cell proliferation. 
 Here, we show a direct interaction between iron metabolism and malignant phenotypes of 
cancer cells, with iron chelation. This presents the possibility of a new therapeutic strategy in cancer. 
 
Materials and methods 
Cell lines and cultures 
The human esophageal cancer cell lines TE4, TE8, TE10, and OE19 were used in this study. They were 
cultured in RPMI 1640 medium (Sigma-Aldrich, MO, US) at 37˚C in humidified air with 5% CO2. 
Medium was supplemented with 10% fetal calf serum (FCS; Hyclone, Logan, UT), 100 units /ml 
penicillin, and 100 mg/ml streptomycin (Sigma-Aldrich). 
 
Reagents 
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Deferasirox, commercialized as EXJADE
TM
, was purchased from Novartis Pharma Co., Ltd. (Tokyo, 
Japan). 
 
Cell viability/cytotoxicity assay 
The proliferation of TE4, TE10 and OE19 cells were evaluated using the XTT assay. Cell viability was 
determined using a Cell Proliferation Kit II (Roche Molecular Biochemicals, Indianapolis, IN) 
according to the manufacturer’s protocol. Cell cytotoxicity (dead cells) were evaluated using 
LIVE/DEAD Viability/Citotoxicity Assay Kit (Molecular Probes, Eugene, OR) acording to the 
manufacture’s protocol. TE4 and TE10 cells (5 × 103) were seeded with 10% FCS. After 24 h 
incubation, the medium was changed to serum-free medium and deferasirox added at each 
concentrations. After 72 h incubation, the each assay was performed. 
 
Migration assay 
Cell migration was determined using 24-well BioCoat cell culture inserts (BD Biosciences, Franklin 
Lakes, NJ). TheTE4 and TE10 cells (5 × 10
4
) were placed in the upper chamber. After 24 h incubation 
with serum-free medium and deferasirox, the cells on the outer surface of the bottom of the filter were 
fixed in formaldehyde, stained with crystal violet (Sigma-Aldrich), and counted with an Olympus IX71 
Microscope (Tokyo, Japan) at a magnification of 100. Three randomly selected fields were counted in 
each group, and the experiment was repeated three times. 
 
Invasion assay 
Cell invasion was determined using 24-well BioCoat cell culture inserts (BD Biosciences) with an 
8-μm-porosity polyethylene terephthalate membrane coated with Matrigel Basement Membrane Matrix. 
TE4 and TE10 cells (5 × 10
4
) were placed in the upper chamber. RPMI 1640 medium with 10% FCS 
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was added to the lower chamber. After 24 h incubation with serum-free medium and deferasirox, the 
cells on the outer surface of the membrane were fixed in formaldehyde, stained with crystal violet 
(Sigma-Aldrich), and counted with an Olympus IX71 Microscope (Tokyo, Japan) at a magnification of 
100. Three fields selected at random were counted in each group, and the experiment was repeated three 
times. 
 
Western blotting 
The TE4 and TE10 cells (5 × 10
3
) were seeded with 10% FCS. After 24 h incubation, the medium was 
changed for serum-free medium and deferasirox added. After 72 h incubation, whole-cell lysates and 
nuclear protein were extracted using M-PER buffer (Thermo Fisher Scientific, Rockford, IL). The 
protein concentrations in the supernatants were measured and equal amounts of protein were 
electrophoresed under reducing conditions on gradient polyacrylamide gels (ATTO, Tokyo, Japan) and 
then transferred onto polyvinylidene difluoride filter membranes (Millipore, Billerica, MA). The 
membranes were incubated with primary antibodies at 4C overnight, followed by incubation with 
secondary antibodies at room temperature for 1 h. An Amersham chemiluminescent ECL Plus Western 
Blotting Detection system (GE Healthcare, Piscataway, NJ) was used for signal detection. The 
following Western blotting materials were used: E-cadherin (Cell Signaling Technology, Inc., Danvers, 
MA), N-cadherin (Takara Bio Inc., Otsu, Japan), β-actin (Sigma-Aldrich), horseradish peroxidase–
conjugated rabbit anti-mouse IgG (Dako Cytomation, Glostrup, Denmark), goat anti-rabbit IgG 
(American Qualex Antibodies, La Mirada, CA). 
 
Quantitative real-time reverse transcription PCR analysis 
TE4 and TE10 cells (5 × 10
4
) were seeded. The cells were treated with serum-free medium and 
deferasirox (100 μM). After 1, 2, 3, 6, and 12 h incubation, total RNA was extracted from cells using a 
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miRNeasy Mini kit (Qiagen, Venlo, Netherlands). The levels of E-cadherin and N-cadherin mRNA 
expression were determined using quantitative real-time PCR and a Step One Plus Real Time PCR 
System (Applied Biosystems, Foster City, CA). The relative levels of E-cadherin and N-cadherin 
mRNA expression were calculated using the 2
−ΔΔCt
 method after normalization with reference to the 
expression of GAPDH mRNA (32 22). 
 
Sphere-forming assay 
To determine migration and invasion ability on 3D culture, the sphere-forming assay was used, as 
reported previously (33 23). TE4 and TE8 cells (5 × 10
3
) were added into 96-well plates with 1.5% 
agarose and RPMI 1640 (1:1). After forming spheres, the cells were fed with serum-free growth 
medium and deferasirox; spheres were photographed after 3 days. 
 
N-cadherin small interference RNA transfection 
To confirm the effect of N-cadherin on migration and invasion activity in esophageal cancer cells, we 
transfected small interfering RNA (siRNA; 5 nM, 7.5 nM). We prepared pre-designed N-cadherin 
targeting siRNA and unlabeled siRNA (Applied Biosystems). TE4 and TE10 cells were transfected with 
siRNAs according to the manufacturer’s instructions.  
 
Animal experiments 
The animal experimental protocol was approved by the Ethics Review Committee for Animal 
Experimentation of Okayama University, Okayama, Japan. All of the mice, the iron-deficient diet, and 
the normal diet were purchased from Clea (Clea, Tokyo, Japan). The 6-week-old male BALB/c nu/nu 
mice were randomized into two groups of eight mice each: (i) normal diet as a control, (ii) iron-deficient 
diet (Table S1). After 3 weeks, subcutaneous xenografts were produced on the backs of mice by 
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injecting 3 × 10
6
 cells mixed with Matrigel (BD Biosciences) at a 1:1 ratio. Water was provided to drink 
freely. Tumor volume was measured weekly (1/2 × length × width
2
). 
 
Statistical analysis 
A Student’s t-test was used to compare data between the two groups. Data represent the mean  SEM; 
*p ≦ 0.05 was considered statistically significant. 
 
Results 
Esophageal tumor growth was suppressed under decreased iron conditions 
 First, we made a decreased iron mouse model using the iron-deficient diet as described 
previously (20). The iron-deficient and normal diets were prepared as described in Table I. We next 
investigated the growth of esophageal tumor under the decreased iron conditions. Nude mice were 
divided into two groups to receive normal or iron-deficient diet. TE4 subcutaneous xenografts were 
produced on the backs of mice after 3 weeks of iron-deficient diet feed. Tumor size was measured twice 
a week. Tumor growth was significantly suppressed in the iron-deficient group (tumor volume: normal 
diet vs iron-deficient diet = 3071.0±1110.7 vs 1056.0±202.4 mm
3
; p=0.003). Tumors in the 
iron-deficient group showed slower growth and their curve rose more gradually compared with the 
normal-diet group (Fig. 1A, C). The similar results were observed in TE8 (Fig. 1B). The standard errors 
each day were also smaller due to overall poor growth. No mice died and no significant side effects 
were observed during the period of experimentation. Thus, esophageal tumor growth is suppressed in 
decreased iron conditions in mouse models, similar to our previous results with lung cancer tumors (20). 
 
Decreased iron conditions inhibited esophageal cancer cell proliferation in vitro 
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 To reproduce the iron-deficient conditions in vitro, the iron chelator deferasirox was used. We 
prepared several esophageal cancer cell lines (TE4 and TE10, squamous-cell carcinoma; OE19, 
adenocarcinoma). Cell viability was measured by XTT assay and cytotoxicity was measured by 
LIVE/DEAD assay after 72 h deferasirox treatment. Deferasirox suppressed proliferation of all cell 
lines in a dose-dependent manner (Fig. 2A), whereas dead cells were increased in high dose of 
deferasirox (1000µM) (Fig.2B). These results suggested that decreased iron condition effect rather on 
cell proliferation than cytotoxicity.   
 
Decreased iron conditions suppressed migration and invasion abilities of esophageal cancer cells 
 To determine other anti-cancer effects concerning the malignant abilities of cancer under 
decreased iron conditions, we investigated the migration and invasion ability of esophageal cancer cells. 
Migration and invasion abilities were measured using double-layer chambers, migrating and invading 
esophageal cancer cells were counted in the bottom chamber. The migration and invasion abilities of 
TE4 and TE10 cells were suppressed by deferasirox in a dose-dependent manner (Fig. 3A,B). 
Furthermore, these abilities were confirmed in a three-dimensional sphere-forming assay, which is more 
similar to biological conditions in a human. Sphere formation of TE4 and TE10 cells was suppressed by 
deferasirox in a dose-dependent manner (Fig. 3C) but OE19 cells were not affected significantly by the 
deferasirox in this assay. These results demonstrate that decreased iron conditions suppress migration 
and invasion abilities of TE4 and TE10 cells. 
 
Migration and invasion abilities were suppressed by inhibiting expression of N-cadherin under 
decreased iron conditions 
 To identify the mechanism of suppression of migration and invasion abilities under decreased 
iron conditions, we focused on the intercellular adhesion molecule cadherin. Western blot analysis 
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showed that N-cadherin expression was suppressed in a dose-dependent manner under decreased iron 
conditions (Fig. 4A), while E-cadherin expression was unchanged. Next, we investigated the mRNA 
status of N-cadherin and E-cadherin. Expression of N-cadherin mRNA was suppressed under decreased 
iron conditions in a time-dependent manner (Fig. 4B). The mRNA expression response was rapid and 
clearly observed after 1 h stimulation. Expression of E-cadherin mRNA was unchanged, as in the 
protein assay. N-cadherin has been reported to be a key molecule for migration and invasion ability. 
Thus, these results suggest that migration and invasion abilities were suppressed by inhibition of 
N-cadherin expression under the decreased iron conditions. 
 
N-cadherin knockdown specifically inhibited migration and invasion abilities of esophageal 
cancer cells 
 To confirm that N-cadherin ruled over the migration and invasion abilities of esophageal 
cancer cells, we made N-cadherin knockdown TE4 and TE10 cells using siRNA. Western blot analysis 
proved that expression of N-cadherin was inhibited by siRNA in both TE4 and TE10 cells (Fig. 5A). 
N-cadherin knockdown TE4 and TE10 cells had equivalent proliferation ability to normal TE4 and 
TE10 cells (Fig. 5B), which suggests that N-cadherin control is not related to cell proliferation. 
However, migration and invasion assays showed the migration ability of N-cadherin knockdown cancer 
cells to be inhibited in the same way as by deferasirox, suggesting that such cell malignancy abilities 
strongly depend on N-cadherin (N-cadherin knockdown TE4 vs negative control TE4 = 30.0±4.90 vs 
84.0±5.35/field; p=0.00046, N-cadherin knockdown TE10 vs negative control TE10 = 5.3±0.47 vs 
12.0±2.45/field; p=0.01944) (Fig. 6A, B). Sphere formation by TE4 and TE10 cells was also clearly 
suppressed by N-cadherin knockdown (Fig. 6C). These results suggest that N-cadherin rules over the 
migration and invasion abilities of esophageal cancer cells and that decreased iron conditions suppress 
the migration and invasion abilities of esophageal cancer cell via suppression of N-cadherin. 
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Discussion 
 Iron is an essential element for mammals, involved in oxygen transport, intracellular DNA 
synthesis, and cell-cycle progression (24, 25). Mounting reports of in vitro and in vivo experiments have 
suggested its potential role in the carcinogenesis process (26-29). Particularly in gastrointestinal tumors, 
breakdown of intracellular iron regulation has been reported in esophageal (30) and colon cancers (31), 
where intracellular molecules related to iron transport and metabolism were demonstrated to be 
modified. All of these reports support iron’s key role in carcinogenesis and its position as a target in 
cancer regulation.  
 We have reported that iron depletion has an inhibitory effect on cancer progression in lung 
cancer cells, and a synergistic effect on anti-angiogenic therapy. The iron-depletion conditions were 
induced by an iron-depletion diet or administration of the iron chelator deferasirox (20). In this study, 
we adopted both methods. This is the first report of an iron-depletion diet in an esophageal cancer 
model. Iron has been reported to induce cell-cycle regulation (32); the same report showed iron to be a 
sensitizer of chemotherapy. Similarly, our data showed down-regulation of cyclin-D1, confirming that 
the inhibitory effect is based on regulation of cell cycle signaling. 
 Regarding the relationship between iron conditions and cancer malignancy, many reports 
regarding EMT have been published recently, showing that iron chelation inhibits TGF- -induced 
EMT (21). We used deferasirox to analyze EMT-related proteins in esophageal cancer, and discovered 
that iron chelation induced down-regulation of N-cadherin expression, up-regulation of which is the 
well-known cadherin-switch in EMT. However, other EMT-related proteins represented by E-cadherin 
were not affected. It seems that iron depletion does not regulate the whole EMT mechanism but at least 
partially affects functional signaling via the key molecule N-cadherin. 
 Although poor prognosis in esophageal cancer patients is led by tumor metastasis and local 
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invasion, the mechanisms have not yet been analyzed. As many studies have already demonstrated that 
N-cadherin is directly related to and affects cellular invasiveness or migration in several cancers (14-16), 
we hypothesized that its expression is regulated by iron chelation and directly related to those malignant 
features. Therefore, we assessed whether cellular iron status affects the malignant features of cancer 
cells, such as invasiveness and migration, that are directly associated with mortality. As expected, in 
vitro assays demonstrated that iron chelation decreased the invasion and migration ability of cancer cells. 
Furthermore a three-dimensional in vitro model, the sphere formation assay (33), which is more 
representative of human conditions, showed similar results to the two-dimensional in vitro model. 
Invasion and migration seem to depend on N-cadherin expression, confirmed by the fact that a cell line 
that does not express N-cadherin is unaffected by iron chelation and by the N-cadherin inhibition 
experiments with siRNA techniques. 
 The importance of our discovery is highlighted by the fact that deferasirox, originally designed 
to regulate iron levels, has the broad antitumor abilities to regulate cell proliferation and mesenchymal 
properties, such as motile and invasive abilities, simultaneously. Compared with current molecularly 
targeted chemotherapy, chelating or controlling iron might be less invasive, safer therapy. Considering 
these results, our investigation provides a new chemotherapeutic strategy. As both features might 
connect directly to patient damage and eventual mortality, controlling iron has the potential to improve 
patient survival and their quality of life post major treatment. Especially in esophageal cancer, distal 
metastasis or local invasion is common even during the early stages. We have presented the highly 
novel finding that iron chelation has the potential to regulate cancer progression by inhibition of 
proliferation and mesenchymal features. 
 We note several limitations of this study. We still need to look into other cancer cell lines as 
well as esophageal cancer, and further analysis with metastatic models in vivo is necessary to prove how 
to contribute to clinical prognosis. In addition to N-cadherin regulation in iron chelation, other possible 
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means of regulation of the cell motility system must be examined. In conclusion, we have shown that 
iron depletion leads to reduced cancer cell growth, invasiveness, and migration through suppression of 
N-cadherin expression. This novel observation is opening new approaches for cancer therapy using 
nutrition.  
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Table and Figure legends 
Table I. Content of control and iron-deficient diets 
 
Figure 1. Tumor growth in decreased iron conditions 
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(A, B) Iron-deficient diet was started 3 weeks before injecting TE4 and TE8 cells on the back of mice. 
The iron-deficient diet was given continuously until the end of study. Tumor volume was measured 
twice a week (1/2 × length × width
2
) and tracked up to 4 weeks. Tumor growth was expressed as mean 
tumor volume ± SEM. Statistical significance (*) was determined as p ≦ 0.05. (C) The photograph was 
taken on day 28 and showed that the tumor growth of TE4 was suppressed in the iron-deficient diet 
group. 
 
Figure 2. Cancer-cell proliferation in decreased iron conditions 
Decreased iron conditions were made using the iron chelator deferasirox. Cultured TE4, TE10, and 
OE19 cells were treated with the indicated concentrations of deferasirox for 72 hours. (A) Cell viability 
was measured by XTT assay and (B) dead cell was measured by LIVE/DEAD assay. Decreased iron 
conditions inhibited cancer cell proliferation in a dose-dependent manner. 
 
Figure 3. Migration and invasion abilities of esophageal cancer cells in decreased iron conditions 
(A) Cultured TE4 and TE10 cells were treated with the indicated concentrations of deferasirox for 24 h. 
The migrated cells were counted. (B) Cultured TE4 and TE10 cells were treated with the indicated 
concentrations of deferasirox for 24 h. The invaded cells were counted. The migration and invasion 
abilities were suppressed under decreased iron conditions. (C) Cultured TE4, TE10, and OE19 cells in 
the sphere formation assay were treated with the indicated concentrations of deferasirox for 72 h. The 
photograph shows that sphere formation of TE4 and TE10 was suppressed under decreased iron 
conditions. Statistical significance (*) was determined as p ≦ 0.05. 
 
Figure 4. Migration and invasion abilities of cancer cells were suppressed by inhibition of 
Nishitani et al.  
 
N-cadherin in decreased iron conditions 
(A) Whole-cell lysates of TE4 and TE10 cells treated with the indicated concentrations of deferasirox 
for 48 h were used in the Western blot analysis. Expression of N-cadherin and cyclin D1 were 
suppressed by deferasirox in a dose-dependent manner. (B) Total RNA of TE4 and TE10 cells treated 
with deferasirox (100μM) for 1, 2, 3, 6, 12 h were used in the PCR analysis. The mRNA of N-cadherin 
was suppressed by deferasirox in a time-dependent manner. Statistical significance (*) was determined 
as p ≦ 0.05. 
 
Figure 5. N-cadherin knockdown inhibited the migration and invasion abilities of cancer cells 
(A) TE4 and TE10 cells were transfected with siRNA. N-cadherin-targeting siRNA knocked down 
N-cadherin. (B) The proliferation of transfected TE4 and TE10 cells was measured. The proliferative 
ability of transfected cells showed the same viability compared with the normal and unlabeled 
siRNA-transfected cells.  
 
Figure 6. N-cadherin knockdown inhibited migration and invasion abilities 
(A, B) TE4 and TE10 cells transfected with N-cadherin targeting siRNA were cultured for 24 h. 
Migrated and invaded cells were counted. (C) In the sphere-formation assay, the cells were cultured for 
72 h. N-cadherin knockdown inhibited migration and invasion abilities in these 3D assays as well as the 
2D culture models. Statistical significance (*) was determined as p ≦ 0.05. 
 
 Table I. Content of control and iron-deficient diets 
  Control diet Iron-deficient diet 
  g/kg diet 
Corn starch 610 610 
Casein 220 220 
Celluose 50 50 
Soybean oil 40 40 
Vitamin mixture 10 10 
Mineral mixture 
  
 Potassium 17.3 17.3 
 Phosphorus 15 15 
 Calcium 13.55 13.55 
 Magnesium 8 8 
 Corn starch 8 9.9 
 Sodium 6 6 
 Iron 1.9 
 
 Manganese 0.154 0.154 
 Zinc 0.06 0.06 
 Iodine 0.0154 0.0154 
 Copper 0.0126 0.0126 
 Chloride 0.004 0.004 
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Figure 4. Migration and invasion abilities of cancer cells were suppressed by
inhibition of N-cadherin in decreased iron conditions
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Figure 5. N-cadherin knockdown inhibited the migration and invasion
abilities of cancer cells
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